Sector News

Merck buys OncoEthix for $375m

December 19, 2014
Life sciences
Just days after announcing its mega-deal with Cubist Merck & Co is on the acquisition trial again with its sights set on private Swiss cancer biotech OncoEthix.
 
The drug giant, which is known as MSD outside the US and Canada, said today it is acquiring the firm to expand its oncology profile, taking OncoEthix’ novel oral BET (bromodomain) inhibitors – including lead candidate OTX015 – into its fold.
 
OTX015, which is currently being tested in Phase Ib studies for the treatment of haematological malignancies and advanced solid tumours, “has demonstrated early promising activity” and “strategically complements” Merck’s immuno-oncology development program, the firm said.
 
From the other side, OncoEthix said it is confident that the deal “best positions OTX015 to be developed to its full potential in areas of high unmet medical need”.
 
Under the deal, Merck will hand out an upfront payment of $110 million to OncoEthix, as well as additional milestone payments of up to $265 million if certain clinical and regulatory events are achieved.
 
By Selina McKee
 
Source: Pharma Times

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend